Following a brief discussion of the epidemiology, underlying neuropathological mechanisms, neuropsychological symptoms and present treatment strategies of AIDS-associated dementia (AAD), parallels are drawn between the longer standing research on drugs for the treatment of other cognitive disorders, particularly senile dementia, and ongoing efforts to develop psychopharmacological approaches for the treatment of the cognitive impairments in AAD. Important aspects of hypotheses designed to guide such a research are indicated with the help of a speculative, paradigmatic hypothesis concerning the role of cortical cholinergic inputs in AAD. Furthermore, aspects of validity of animal models, and cognition as a crucial intervening variable in the effects of potential treatments, are evaluated.
Adamson D C, Wildemann B, Sasaki M, Glass D J, McArthur J C, Christow V I, Dawson T M, Dawson V L (1996) Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 coat protein, gp41. Science274: 1917–1921
2.
Adamson D C, Kopinsky K L, Dawson T M, Dawson V L (1999) Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity. J Neurosci19: 64–71
3.
Aggoun-Zouaoui D, Charriaut-Marlangue C, Rivera S, Jorquera I, Ben-Ari Y, Represa A (1996) The HIV-1 envelope protein gp120 induces neuronal apoptosis in hippocampal slices. Neuroreport7: 433–436
4.
An S F, Giometto B, Scaravilli F (1996) HIV-1 DNA in brains in AIDS and pre-AIDS: correlation with the stage of disease. Ann Neurol40: 611–617
5.
Asare E, Dunn G, Glass J, McArthur J, Luthert P, Lanots P, Everall I (1996) Neuronal pattern correlates with the severity of human immunodeficiency virus-associated dementia complex. Am J Pathol148: 31–38
6.
Auld D S, Kar S, Quirion R (1998) β-amyloid peptides as direct cholinergic neuromodulators: a missing link?Trends Neurosci21: 43–49
7.
Bacellar H, Munoz A, Miller E N, Cohen B A, Besley D, Selnes O A, Becker J T, McArthur J C (1994) Temporal trends in the incidence of HIV-1 related neurologic diseases: multicenter AIDS cohort study. 1998–1992. Neurology44: 1892–1900
8.
Barks J D, Liu X H, Sun R, Silverstein F S (1997) GP120, a human immunodeficiency virus-1 coat protein, augments excitotoxic hippocampal injury in perinatal rats. Neurosci76: 397–409
9.
Belman A L (1993) Neurologic syndromes. In Lyman W D, Rubinstein A (eds) Pediatric AIDS: clinical, pathologic, and basic science perspectives. Ann NY Acad Sci 693: 107–122
10.
Belman A L (1997) Infants, children, and adolescents. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 223–253
11.
Bell J E, Brettle R P, Chiswick A, Simmonds P (1998) HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain121: 2043–2052
12.
Bendok B, Berger J R, Levy R M (1997) Acquired immunodeficiency syndrome and the nervous system: Fifteen years of Progress. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 1–11
13.
Bishburg E, Eng R H K, Slim J, Perez G, Johnson E (1989) Brian lesions in patients with acquired immunodeficiency syndrome. Arch Intern Med149: 941–943
14.
Bjugstad K B, Flitter W D, Garland W A, Su G C, Arendash G W (1998) Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res795: 349–357
15.
Bornstein R A, Nashralla H A, Para M F, Fas R J, Whitacre C C, Rice R R (1991) Rate of CD4 decline and neuropsychological performance in HIV infection. Arch Neurol48: 704–404
16.
Bloom F E, Rausch D M (1997) HIV in the brain: pathology and neurobehavioral consequences. J Neurovirol3: 102–109
17.
Bragg C D, Meeker R B, Duff B A, English R V, Tompkins M B (1999) Neurotoxicity of FIV and FIV envelope protein in feline cortical cultures. Brain Res816: 431–437
18.
Brodt H R, Kamps B S, Gute P, Knupp B, Staszewski S, Helm E B (1997) Changing incidence of AIDS defining illness in the era of antiretroviral combination therapy. AIDS11: 1731–1738
19.
Cherkaoui J, Mayo W, Neveu P J, Kelley K W, Vitiello S, Le Moal M, Simon H (1990) The nucleus basalis is involved in brain modulation of the immune system in rats. Brain Res516: 345–348
20.
Cho E S, Sharer L R (1990) HIV encephalopathy in children. In Kozlowski P B, Snider D A, Vietze P M, Wisniewski H M (eds), Brain in pediatric AIDS. S. Karger, Basel, pp. 158–164
21.
Dal Pan G J, McArthur J H, Aylward E, Selnes O A, Nance-Sproson T E, Kumar A J, Mellits E D, McArthur J C (1992) Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology42: 2125–2130
22.
Dal Pan G, McArthur J C, Harrison M J (1997) Neurological symptoms in human immunodeficiency virus infection. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 141–172
23.
Damos D L, John R S, Parker E S, Levine A M (1997) Cognitive function in asymptotic HIV infection. Arch Neurol54: 179–185
24.
Day J J, Grant I, Atkinson J H, Brysk L T, McCutchan J A, Hesselink J R, Heaton R K, Weinrich J D, Spector S A, Richman D D (1992) Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort. J Neuropsych Clin Neurosci4: 15–20
25.
Depboylu C, Bette M, Schäfer M K H, Vertesi R, Eiden L EWeihe H (1999) Cyclooxygenase-2 is coexpressed in primate cholinergic basal forebrain neurons and downregulated in SIV-infection in rhesus monkeys. Soc Neurosci Abstr25: 25.12-25.12
26.
Dickson D W, Lee S C, Mattiace L A, Yen S H, Brosnan C (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia7: 75–83
27.
Epstein L G, Gendelman H F, Lipton S A (1997) Human immunodeficiency virus-1 neuropathogenesis. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 59–75
28.
Everitt B J, Robbins T W (1997) Central cholinergic systems and cognition. Ann Rev Psychol48: 649–684
29.
Fatkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A, Salzberger B (1997) Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS11: F113–F116
30.
Felder C C, Ma A I, Briley E M, Axelrod J (1993) Muscarinic acetylcholine receptor subtypes associated with release of amyloid precursor derivatives activate multiple signal transduction pathways. Ann NY Acad Sci695: 15–18
31.
Fredj G, Dietlin F, Jasmin C, Maurisson G, Barbier M, Bayce P, Ratiney R, Rudant E, Debat P, Kalifa D, Mayer P, Misset J L, Bonhomme L (1992) Open trial of tacrine therapy in 70 HIV-infected patients. Int J Clin Pharmacol Ther Toxicol30: 313–316
32.
Gelbard H A, Nottet H S, Swindells S, Jett M, Dzenko K A, Genis P, White P, Wang L, Choi Y B, Zhang D, Lipton S, Tourtellotte W W, Epstein L G, Gendelman H E (1994) Platelet-activating factor: A candidate human immunodeficiency virus type-1 neurotoxin. J Virol68: 4628–4635
33.
Gelman B B, Guinto F C (1992) Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome. Ann Neurol32: 31–40
34.
Glass J D, Johnson, R T (1996) Human immunodeficiency virus and the brain. Ann Rev Neurosci19: 1–26
35.
Glowa J R, Panlilio L V, Brenneman D E, Gozes I, Fridkin M, Hill J M (1992) Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res570: 49–53
36.
Gray F, Haug H, Chimelli L, Geny C, Gaston A, Scaravilli F, Budka H (1991) Prominent cortical atrophy with neuronal loss as correlate of human immunodeficiency virus encephalopathy. Acta Neuropathol82: 229–233
37.
Gruol D L, Yu N, Parsons K L, Billaud J N, Elder J H, Phillips T R (1998) Neurotoxic effects of feline immunodeficiency virus, FIVPPR. J Neurovirol4: 415–425
38.
Hall M, Whaley R, Robertson K, Hamby S, Wilkins J, Hall C (1996) The correlation between neuropsychological and neuroanatomic changes over time in asymptomatic and symptomatic HIV-1-infected individuals. Neurology46: 1697–1702
39.
Heyes M P, Brew B J, Martin A, Price R W, Salazar A M, Sidtis J J, Yergey J A, Mouradian M M, Sadler A E, Keilp J. (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol29: 202–209
40.
Janssen R S, Nwanyanwu O C, Selik R M, Stehr-Green J K (1992) Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology42: 1472–1476
41.
Janssen R S (1997) Epidemiology and neuroepidemiology of human immunodeficiency virus infection. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 13–38
42.
Jernigan T L, Archibald S, Hesselink J R, Atkinson J H, Velin R A, McCutchan J A, Chandler J, Grant I (1993) Magnetic resonance imaging morphometric analysis of cerebral volume loss in human immunodeficiency virus infection. The HNRC Group. Arch Neurol50: 250–255
43.
Kehne J H, Baron B M, Harrison B L, McCloskey T C, Palfreyman M G, Poirot M, Salituro F G, Siegel B W, Slone A M, Van Giersbergen P L M, White H S (1995) MDL 100 458 and MDL 102 288: two potent and selective glycine receptor antagonists with different functional profiles. Europ J Pharmacol284: 109–118
44.
Keith R A, Mangano T J, Meiners B A, Stumpo R J, Klika A B, Patel J, Salama A I (1989) HA-966 acts at a modulatory glycine site to inhibit N-methyl-D-aspartate-evoked neurotransmitter release. Eur J Pharmacol166: 393–400
45.
Kelly J S (1999) Alzheimer's disease: the tacrine legacy. Trends Pharmacol Sci20: 127–129
46.
Ketzler S, Weis S, Haug H, Budka H (1990) Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol80: 92–94
47.
Kieburtz K D, Epstein L G, Gelbard H A, Greenmayre J T (1991) Excitotoxic and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Arch Neurol48: 1281–1284
48.
Kieburtz K D [The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders] (1997) Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. Neurology49: 142–146
49.
Kopelman M D, Lishman W A (1986) Pharmacological treatments of dementia (non-cholinergic). Br Med Bull42: 101–105
50.
Krucker T, Toggas S M, Mucke L, Siggins G R (1998) Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short-and long-term potentiation in CA1 hippocampus. Neuroscience83: 691–700
51.
Kustova Y, Ha J H, Espey M G, Sei Y, Morese D, Basile D S (1998) The pattern of neurotransmitter alterations in LP-BM5 infected mice is consistent with glutamatergic hyperactivation. Brain Res793: 119–126
52.
Law W A, Martin A, Mapou R L, Roller T L, Salazar A M, Temoshok L R, Rundell J R (1994) Working memory in individuals with HIV infection. J Clin Expl Neuropsychol16: 173–182
53.
Law W A, Mapou R L, Roller T L, Martin A, Nannis E D, Temoshok L R (1995) Reaction time slowing in HIV-1 infected individuals: role of the preparatory interval. J Clin Expl Neuropsychol17: 122–133
54.
Liberini P, Pioro E P, Maysinger D, Cuello A C (1994) Neocortical infarction in subhuman primates leads to restricted morphological damage of the cholinergic neurons in the nucleus basalis of Meynert. Brain Res648: 1–8
55.
Lipton S A (1992) Models of neuronal injury in AIDS: another role for the NMDA receptor. Trends Neurosci15: 75–79
56.
Lipton S A, Gendelman H E (1995) Dementia associated with the acquired immunodeficiency syndrome. New Engl J Med14: 934–940
57.
Lipton S A (1998) Neuronal injury associated with HIV-1: approaches to treatment. Ann Rev Pharm Toxicol. 38: 159–177
58.
Lipton S A, Kieburtz K D (1998) Development of adjunctive therapies for the neurologic manifestations of AIDS: Dementia and painful neuropathy. In Gendelman H E, Lipton S A, Epstein L, Swindells S (eds), The neurology of AIDS. Chapman and Hall, New York, pp. 377–384
59.
Marder et al. [The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders] (1996). Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. Neurology47: 1247–1253
60.
Masliah E, Achim C L, Ge N, DeTeresa R, Terry R D, Wiley C A (1992) Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol32: 321–329
61.
Masliah E, Ge N, Achim C L, Wiley C A (1995) Differential vulnerability of calbindinimmunoreactive neurons in HIV encephalitis. J Neuropathol Expl Neurol54: 350–357
62.
McArthur J, Grant I (1998) HIV Neurocognitive Disorders. In Gendelman H E, Lipton S A, Epstein L, Swindells S (eds), The neurology of AIDS. Chapman and Hall, New York, pp. 499–523
63.
McArthur J C, Selnes O A (1997) Human immunodeficiency virus associated dementia. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 527–567
64.
McArthur J C, Hoover D R, Bacellar H, Miller E N, Cohen B A, Becker, J T, Graham N M, McArthur J H (1993) Dementia in AIDS patients: incidence and risk factors. Neurology43: 2245–2252
65.
McGaughy J, Sarter M (1995) Behavioral vigilance in rats: Task validation and effects of age, amphetamine, and benzodiazepine receptor ligands. Psychopharmacol117: 340–357
66.
McGaughy J, Turchi J, Sarter M (1994) Crossmodal divided attention in rats: effects of chlordiazepoxide and scopolamine. Psychopharmacology115: 213–220
67.
McGaughy J, Kaiser T, Sarter M (1996) Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behav Neurosci110: 247–265
68.
McGuire D, Marder K (2000) Pharmacologic frontiers in the treatment of AIDS dementia. J Psychopharmacol14: 000–000
69.
Mitrushina M, D'Elia L, Satz P, Uchiyama C, Mathews A, Harker J (1993) A comparison of selective attention deficits in normal elderly and AIDS patients. Develop Brain Dysfunct6: 324–328
70.
Murray E A, Rausch D M, Lendvay J, Sharer L R, Eiden L E (1992) Cognitive and motor impairments associated with SIV infection in rhesus monkeys. Science255: 1246–1249
71.
Narayan O, Stephens E B, Joag S V, Chebloune Y (1997) Animal models of human immunodeficiency virus neurological disease. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 123–140
72.
Nath A (1998) Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Progr Neurobiol54: 19–33
73.
Navia B A, Jordan B D, Price R W (1986a) The AIDS dementia complex: I. clinical features. Ann Neurol19: 517–524
74.
Navia B A, Cho E S, Peitio C K, Price R W (1986b) The AIDS dementia complex: II. neuropathology. Ann Neurol19: 525–535
75.
Neveu P J (1988) Cerebral cortex modulaiton of immune function. Life Sci42: 1917–1923
76.
Page K J, Everitt B J (1995) The distribution of neurons coexpressing immunoreactivity to AMPA-sensitive glutamate receptor subtypes (GluR1–4) and nerve growth factor receptor in the rat basal forebrain. Eur J Neurosci7: 1022–1033
77.
Parsons C G, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data. Neuropharmacology38: 735–767
78.
Pearson R C A, Gatter K, Powell T P S (1983) Retrograde cell degeneration in the basal nucleus in monkey and man. Brain Res261: 375–379
79.
Perkins D O, Leserman J, Stern R A, Baum S F, Liao D, Golden R N, Evans D L (1995) Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry152: 1776–1781#
80.
Pizzo P A, Eddy J, Falloon J, Balis F M, Murphy R F, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, et al. (1988) Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection [see comments]. N Engl J Med319: 889–896
81.
Podell M, Oglesbee M, Mathes L, Krakowka S, Olmstead R, Lafado L (1993) AIDS-associated encephalopathy with experimental feline immunodeficiency virus infection. J Acquir Immune Defic Syndr6: 758–771
82.
Podell M, March P A, Buck W R, Mathes L E (2000a) The feline model of neuroAIDS: understanding the progression towards AIDS dementia. J Psychopharmacol14: 000–000
83.
Podell M, Maruyama K, Smith M, Hayes K, Buck W R, Ruehlmann D, Mathes L (2000b) Frontal lobe injury correlates to altered function in FIV-infected cats. J AIDS Hum Retrovirol22: 10–18
84.
Power C, Moench T, Peeling J, Kong P A, Langelier T (1997) Feline immunodeficiency virus causes increases glutamate levels and neuronal loss in brain. Neuroscience77: 1175–1185
85.
Price R W, Brew B, Sidtis J, Rosenblum M, Scheck A C, Clearly P (1988) The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science239: 586–592
86.
Reinvang I, Froland S S, Skripeland V (1991) Prevalence of neuropsychological deficit in HIV infection. Incipient signs of AIDS dementia complex in patients with AIDS. Acta Neurol Scand83: 289–293
87.
Renoux G, Biziere K, Renoux M, Guillaumin J M, Degenne D A (1983) The production of T-cell inducing factors is controlled by brain neocortex. Scand J Immunol17: 45–50
88.
Riedel R R, Helmstaedter C, Blulau H F, Brackman H, Fimmer R, Clarenbach P, Miller E N (1992) Early signs of cognitive deficits among human immunodeficiency virus-positive hemophiliacs. Acta Psychiatr Scand85: 321–326
89.
Sacktor N, McArthur J (1997) Prospects for therapy of HIV-associated neurologic diseases. J Neurovirol3: 89–101
90.
Sacktor N C, Lyles R H, Skolasky R L, Andersen D E, McArthur M C, McFarlane G, Selnes O A, Becker J T, Cohen B, Wesch J, Miller EN (1999) Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Neurology52: 1640–1647
91.
Sahakian B J, Elliott R, Mehta M, Clark R T, Pozniak A L (1995) Neuropsychological deficits in test of executive function in asymptomatic and symptomatic HIV-1 seropositive men. Psychol Med25: 1233–1246
92.
Salvan A M, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone P J (1997) Cerebral metabolic alterations in human immunodeficiency virus-related encephalopathy detected by proton magnetic resonance spectroscopy. Comparison between sequences using short and long echo times. Invest Radiol32: 485–495
93.
Sarter M, Bruno J P (1994) Cognitive functions of cortical ACh [acetylcholine]: lessons from studies on the trans-synaptic modulation of activated efflux. Trends Neurosci17: 217–221
94.
Sarter M, Bruno J P (1997) Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Rev23: 28–46
95.
Sarter M, Bruno J P (1999) Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends Neurosci22: 67–74
96.
Sarter M, Dudchenko P (1991) Dissociative effects of ibotenic acid and quisqualic acid-induced basal forebrain lesions on cortical acetylcholinesterase-positive fiber density and cytochrome oxidase activity. Neuroscience41: 729–738
97.
Sarter M, Hagan, J, Dudchenko P (1992a) Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part I. Psychopharmacology107: 144–159
98.
Sarter M, Hagan, J, Dudchenko P (1992b) Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part II. Psychopharmacology107: 461–473
99.
Sarter M, Bruno J P, Givens B, Moore H, McGaughy J, McMahon K (1996) Neuronal mechanisms mediating drug-induced cognition enhancement: cognitive activity as a necessary intervening variable. Cognit Brain Res3: 329–343
100.
Sarter M, Bruno J P, Himmelheber A M (1997) Cortical acetylcholine and attention: neuropharmacological and cognitive principles directing treatment strategies for cognitive disorders. In Brioni J E, Decker M W (eds), Pharmacological treatment of Alzheimer's Disease: molecular and neurobiological foundations. New York: Wiley-Liss, pp. 105–128
101.
Sarter M, Bruno J P, Turchi J (1999) Ventral striatal-basal forebrain mechanisms modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. In McGinty J F (ed.), Advancing from the ventral striatum to the extended amygdala. Ann NY Acad Sci 877: 368–382
102.
Schmitt F A, Wetherby M M C, Stern Y (1997) Neuropsychological changes in human immunodeficiency virus infection. In Berger J R, Levy R M (eds), AIDS and the nervous system. Lippincott-Raven, Philadelphia, pp. 401–417
103.
Selnes O A, Galai N, Bacellar H, Miller E N, Becker J T, Wesch J, Van Gorp W, McArthur J C (1995) Cognitive performance after progression to AIDS. Neurology45: 267–275
104.
Sidtis J J, Gatsonis C, Price R W, Singer E J, Collier A C, Richman D D, Hirsch M S, Schaerf F W, Fischi M A, Kieburtza K et al. (1993) Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol33:343–349
105.
Steigerwald E S, Sarter M, March P, Podell M (1999) Effects of FIV on cognition and behavioral function in cats. J Acquir Immune Defic Syndr Hum Retrovirol20: 411–419
106.
Stout J C, Salmon D P, Butters N, Taylor M, Peavy G, Heindel W C, Delis D C, Ryan L, Atkinson J H, Chandler J L, Grant I [and the HNRC Group] (1995) Decline in working memory associated with HIV infection. Psychol Med25: 1221–1232
107.
Takahashi K, Wesselingh, S L et al. (1996) Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunohistochemistry. Ann Neurol39: 705–711
108.
Toggas S, Masliah E, Mucke L (1996) Prevention of HIV-1 GP120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res706: 303–307
109.
Turchi J, Sarter M (1997) Cortical acetylcholine and processing capacity: effects of cortical cholinergic deafferentation on crossmodal divided attention in rats. Cognit Brain Res6: 147–158
110.
Weiss J H, Yin H Z, Choi D W (1994) Basal forebrain cholinergic neurons are selectively vulnerable to AMPA/kainate receptor mediated neurotoxicity. Neurosci60: 659–664
111.
Wenk G L (1996) Neuroprotection and selective vulnerability of neurons within the nucleus basalis magnocellularis. Behav Brain Res72: 17–24
112.
Wiley C, Masliah E, Achim C (1994) Measurement of CNS HIV burden and its association with neurologic damage. Adv Neuroimmunol4: 319–325
113.
Wiley C A, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R (1991) Neocortical damage during HIV infection. Ann Neurol29: 651–657
114.
Wilkie F L, Eisdorfer C, Morgan R, Loewenstein D A, Szaporcznik J (1990) Cognition in early human immunodeficiency virus infection. Arch Neurol47: 433–440
115.
Willner P (1991) Methods for assessing the validity of animal models of human psychopathology. In Boulton A, Baker G, Martin-Iverson M (eds), Animal models in psychiatry I. The Humana Press Inc., Clifton, NJ, pp. 1–23
116.
Worth L J, Savage C R, Baer L, Esty E K, Navia B A (1993) Computer-based neuropsychological screening for AIDS dementia complex. AIDS7: 677–681
117.
Wu L, Gerard N P, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso A A, Desjardin E, Newman W, Gerard C, Sodroski J (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with chemokine receptor CCR–5. Nature384: 179–183
118.
Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science280: 1884–1888
